Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Net revenue:
Total net revenues	$ 10,334	$ 5,687
Cost of goods sold	4,250	2,484
Gross margin	6,084	3,203
Operating expenses:
Research and development	3,090	1,539
Depreciation and amortization	186	163
Selling, general and administrative	6,119	4,517
Change in fair value of contingent consideration	(156)
Total operating expenses	9,239	6,219
Loss from operations	(3,155)	(3,016)
Other income (expense):
Loss on extinguishment of debt		(199)
Interest expense	(195)	(172)
Interest income		4
Other expense, net	(54)	(35)
Loss before income taxes	(3,404)	(3,418)
Income tax benefit	225	93
Net loss	(3,179)	(3,325)
Less: Undeclared deemed dividend attributable to noncontrolling interest	(241)	(77)
Net loss attributable to Nephros, Inc. shareholders	$ (3,420)	$ (3,402)
Net loss per common share, basic and diluted	$ (0.45)	$ (0.50)
Weighted average common shares outstanding, basic and diluted	7,542,299	6,846,669
Comprehensive loss:
Net loss	$ (3,179)	$ (3,325)
Other comprehensive loss, foreign currency translation adjustments, net of tax	(6)	(6)
Comprehensive loss	(3,185)	(3,331)
Comprehensive loss attributable to noncontrolling interest	(241)	(77)
Comprehensive loss attributable to Nephros, Inc. shareholders	(3,426)	(3,408)
Product Revenues [Member]
Net revenue:
Total net revenues	10,182	5,457
Royalty and Other Revenues [Member]
Net revenue:
Total net revenues	$ 152	$ 230